Association of PCSK9 with platelet reactivity in patients with acute coronary syndrome treated with prasugrel or ticagrelor: The PCSK9-REACT study

Circulating proprotein convertase subtilisin/kexin type 9 (PCSK9) enzyme might be associated with increased activation of platelets. We aimed to assess the relationship between PCSK9 levels, platelet reactivity and ischemic outcomes. Consecutive ACS patients receiving prasugrel or ticagrelor and und...

Full description

Saved in:

Bibliographic Details
Published in:	International journal of cardiology Vol. 227; pp. 644 - 649
Main Authors:	Navarese, Eliano P., Kolodziejczak, Michalina, Winter, Max-Paul, Alimohammadi, Arman, Lang, Irene M., Buffon, Antonino, Lip, Gregory YH, Siller-Matula, Jolanta M.
Format:	Journal Article
Language:	English
Published:	Netherlands Elsevier B.V 15.01.2017
Subjects:	Acute coronary syndrome Acute Coronary Syndrome - blood Acute Coronary Syndrome - diagnostic imaging Acute Coronary Syndrome - drug therapy Adenosine - analogs & derivatives Adenosine - pharmacology Adenosine - therapeutic use Aged Biomarkers - blood Cardiovascular Coronary Angiography Female Follow-Up Studies Humans Male Middle Aged PCSK9 Platelet Activation - drug effects Platelet Activation - physiology Platelet Aggregation Inhibitors - pharmacology Platelet Aggregation Inhibitors - therapeutic use Platelet reactivity Prasugrel Prasugrel Hydrochloride - pharmacology Prasugrel Hydrochloride - therapeutic use Proprotein Convertase 9 - blood Ticagrelor Treatment Outcome Prasugrel PCSK9 Acute coronary syndrome Ticagrelor Platelet reactivity
ISSN:	0167-5273, 1874-1754, 1874-1754
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!